Table 1 Inhibitory effect of N-[{(2-phenyl)methylidene]-2-(4-ethyl-5-(pyridine-2-yl)-4H-1,2,4-triazole-3-yl)sulfanyl}acetohydrazide (ZE-4b), N-[{(2-phenyl)methylidene]-2-(4-(fluorophenyl-5-(pyridine-2-yl)-4H-1,2,4-triazole-3yl)sulfanyl}acetohydrazide (ZE-4c), N-[{(4-methylphenyl)sulfonyl}]-2-(4-cyclohexyl-5-(pyridine-2-yl)-4H-1,2,4-triazole-3-yl)sulfanyl}acetohydrazide (ZE-5a) and N-[{(4-methylphenyl) sulfonyl}-2-(4-ethyl-5-(pyridine-2-yl)-4H-1,2,4-triazole-3yl)sulfanyl}acetohydrazide (ZE-5b) on arachidonic acid (AA), adenosine diphosphate (ADP) and collagen induced platelet aggregation

4.4 ± 0.09

8.8 ± 0.09

30.3 ± 0.06

41.2 ± 0.23

63.2 ± 0.06

78 ± 0.14

89.5 ± 0.23

0.1 ± 0.03

1.0 ± 0.03

3.6 ± 0.03

9.6 ± 0.06

18.2 ± 0.12

39.4 ± 0.17

54.7 ± 0.18

27.1 ± 0.40

39.2 ± 0.06

49.7 ± 0.11

63.7 ± 0.23

85.7 ± 0.06

43.8 ± 0.35

20.5 ± 0.35

7.9 ± 0.15

15.4 ± 0.20

29 ± 0.21

43 ± 0.18

59 ± 0.03

75 ± 0.10

86.4 ± 0.44

0.1 ± 0.03

2.7 ± 0.06

9.6 ± 0.15

22.5 ± 0.06

32 ± 0.12

39.7 ± 0.23

52.8 ± 0.12

33.5 ± 0.81

42.2 ± 0.24

50 ± 0.32

58.4 ± 0.32

68.4 ± 0.24

80.9 ± 0.26

85.9 ± 0.18

4.0 ± 0.12

7.9 ± 0.06

23.7 ± 0.15

39.5 ± 0.21

47.4 ± 0.12

68 ± 0.35

72.8 ± 0.59

0.1 ± 0.09

1.8 ± 0.06

12.2 ± 0.12

24.3 ± 0.09

28.5 ± 0.12

36.3 ± 0.18

50.9 ± 0.17

23.3 ± 0.11

37.8 ± 0.49

43.3 ± 0.17

49.5 ± 0.23

67.6 ± 0.58

72.9 ± 0.46

81.4 ± 0.11

8.8 ± 0.09

11.4 ± 0.27

25 ± 0.21

30.7 ± 0.58

52.2 ± 0.40

68.4 ± 0.40

79 ± 0.60

1 ± 0.03

3.6 ± 0.06

8.7 ± 0.17

22.5 ± 0.06

37.1 ± 0.14

44.9 ± 0.03

61.2 ± 0.17

21.6 ± 0.35

23.1 ± 0.41

43.8 ± 0.65

51.8 ± 0.43

67.8 ± 0.52

78.6 ± 0.31

91.1 ± 0.67

27.2 ± 0.18

36 ± 0.09

50.1 ± 0.16

59.7 ± 0.09

100 ± 0

100 ± 0

100 ± 0

3.6 ± 0.07

6.2 ± 0.09

19.1 ± 0.07

25 ± 0.06

32.8 ± 0.10

49.8 ± 0.12

56.9 ± 0.18

37.2 ± 0.14

48.7 ± 0.14

57.7 ± 0.20

68.6 ± 0.29

71 ± 0.23

78.6 ± 0.23

98.1 ± 0.11